Application of the revised International Prognostic Scoring System for Myelodysplastic Syndromes in 470 Argentinean patients.

BELLI C; BESTACH Y; BENGIO R; SAKAMOTO F; NUCIFORA E; GONZALEZ J; CRISP R; FAZIO P; PINTOS N; LARRIPA I

Berlin

Congreso; 12th International Symposium on Myelodisplastic Syndromes; 2013

European Hematology Association

The International Prognostic Scoring System (IPSS), the gold standard for risk assessment in Myelodysplastic syndromes (MDS), has been recently revised (IPSS-R) and would prove beneficial for predicting outcomes. The aim of this study was to apply the IPSS-R in Argentinean MDS patients. We retrospectively analyzed a cohort of 470 de novo MDS patients (276 belong to the MDS Registry promoted by the Argentinean Society of Hematology), diagnosed between 1981 and 2012. Initially, all patients were categorized according to FAB system, and 398 (85%) patients were also classified according to WHO classification, and as both classifications were used, RAEBt (7%), CMML (10%), and del(5q) syndrome (5%) were represented. The median age was 70 (17-92) years with 74% of patients above age of 60 years, the gender ratio was 1.3 (M/F: 262/208), and 201 (43%) patients showed an abnormal karyotype. During the follow-up (median overall survival: 43 months), 104 (22%) evolved to AML, and 203 (43%) died. The demographic description, obtained percentages, survival times and time to leukemic evolution for our patients regarding cytogenetic, hematological parameters, and IPSS subgroups were similar to the International Working Group for Prognosis in MDS database. Patients were classified by IPSS-R as very-low (22%), low (40%), intermediate (14%), high (14%), and very-high risk (10%), with median survival of 121, 60, 28, 20 and 14 months (p131, 131, 23, 5, and 5 months, respectively (p